Healthy Volunteer Clinical Trial
Official title:
Effectiveness of Hybrid Learning Mode of Volunteer Training: A Randomized Controlled Trial
Verified date | February 2024 |
Source | Education University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As the effectiveness of the hybrid volunteer training in Hong Kong is under-studied, this experimental study aims to develop a hybrid learning mode of volunteer training that increase volunteering-related self-efficacy and its associated outcomes among volunteer. In particular, this study compares the efficacy of hybrid volunteer training with the wait-list control group. The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses. Each module will consist of the key volunteer training component presented in in written or video format. Materials will be presented interactively to facilitate engagement.
Status | Completed |
Enrollment | 64 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hong Kong residents - Age =18 years - Willing to participate in volunteer service - Being able to read Chinese - Have a computer, tablet and/or smartphone device with Internet access - Have a regular email address - Willing to give informed consent and comply with the trial protocol Exclusion Criteria: - Unable to communicate with Cantonese. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Baptist Oi Kwan Social Service | Hong Kong | |
Hong Kong | The Education University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Education University of Hong Kong | Baptist Oi Kwan Social Service |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Assessment in Self-Efficacy Towards Service on the Self-Efficacy Towards Service (SETS) Scale at Post-intervention Assessment and Follow-up Assessment | The SETS scale assess the change in a 5-point Likert scale, ranging from strongly disagree (1) to strongly agree (5). | Before intervention, Immediately after intervention, and 4 weeks after intervention | |
Primary | Change from Baseline Assessment in Mental Health-related Knowledge on the Mental Health Knowledge Schedule (MAKS) at Post-intervention Assessment and Follow-up Assessment | The MAKS assess the change in a 5-point Likert scale, ranging from strongly disagree (1) to strongly agree (5). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Primary | Change from Baseline Assessment in Views of Empowerment on the Empowerment Scale at Post-intervention Assessment and Follow-up Assessment | The Empowerment Scale assess the change in a 9-point scale of agreement, ranging from strongly disagree (1) to strongly agree (9). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Primary | Change from Baseline Assessment in View of Recovery on the Recovery Scale at Post-intervention Assessment and Follow-up Assessment | The Recovery Scale assess the change in a 9-point scale of agreement, ranging from strongly disagree (1) to strongly agree (9). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Primary | Change from Baseline Assessment in Mental Health-related Behaviors on the Intended Behaviour subscale of the Reported and Intended Behaviour Scale (RIBS) at Post-intervention Assessment and Follow-up Assessment | The RIBS assess the change in a 5-point Likert scale, ranging from strongly disagree to engage in the stated behavior (1) to strongly agree with engaging in the stated behavior (5). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Primary | Change from Baseline Assessment in Public Attitudes Toward Mental Illness on the Stigma and Acceptance Scale at Post-intervention Assessment and Follow-up Assessment | The Stigma and Acceptance Scale assess the change in a 6-point Likert scale, ranging from strongly disagree (1) to strongly agree (6). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Secondary | Change from Baseline Assessment in Psychological Wellbeing on the World Health Organisation-Five Well-Being Index (WHO-5) at Post-intervention Assessment and Follow-up Assessment | The WHO-5 assess the change in a 6-point Likert scale, ranging from at no time (1) to all of the time (6). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Secondary | Change from Baseline Assessment in Anxiety Symptom on the General Anxiety Disorder-7 (GAD-7) at Post-intervention Assessment and Follow-up Assessment | The GAD-7 assess the change in a 4-point Likert scale, ranging from not at all (0) to nearly every day (3). | Before intervention and Immediately after intervention and 4 weeks after intervention | |
Secondary | Change from Baseline Assessment in Depressive Symptom on the Patient Health Questionnaire-9 (PHQ-9) at Post-intervention Assessment and Follow-up Assessment | The PHQ-9 assess the change in a 4-point Likert scale, ranging from not at all (0) to nearly every day (3). | Before intervention and Immediately after intervention, and 4 weeks after intervention | |
Secondary | Change from Baseline Assessment in Quality of Life on the Twelve-item short-form (SF-12) health survey at Post-intervention Assessment and Follow-up Assessment | The SF-12 assesses the change in a combination of 5-point and 3-point Likert scale, ranging respectively from poor/ never (1) to excellent/ very much (5), and never (1) to very much (3). | Before intervention and Immediately after intervention, and 4 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01414881 -
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 |